19-247 - Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Status: openA Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Treatment for Cervical Cancer
Description
This study is a multi-center, single arm, open label trial to evaluate the efficacy and safety of Cabozantinib (XL184) plus Pembrolizumab in recurrent, persistent and/or metastatic cervical cancer with PD-L1 tumor positivity.
Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
![Rocconi Rodney]()
View ProfileRodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistAssociate Director for Clinical Research; Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology![New pic of dr scalici]()
View ProfileJennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Associate Professor of Interdisciplinary Clinical Oncology![Jennifer Young Pierce]()
View ProfileJennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.Gynecologic OncologistResidency Program Director for Obstetrics and Gynecology; Leader of Cancer Control and Prevention; Professor of Interdisciplinary Clinical Oncology![Nathaniel Jones]()
View ProfileNathaniel Jones, M.D.Gynecologic OncologistAssistant Professor of Interdisciplinary Clinical Oncology
This link will open in a new tab or window.